On July 5, 2016, the U.S. Court of Appeals for the Federal Circuit issued an opinion vacating the summary judgment of invalidity of U.S. Patent No. 7,604,929 (“the ’929 Patent”) and sent the case back to the District Court for the Northern District of Illinois. See Rapid Litigation Management Ltd., et al. v. CellzDirect, Inc., et al., No. 2015-1570 (Fed. Cir. Jul. 5, 2016)(“Opinion”). The ’929 Patent is directed to a method of preserving hepatocytes using multiple freeze-thaw cycles. This process is distinct from the prior art, which taught that hepatocytes would remain viable only after a single freeze-thaw cycle.
